| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.921 | 0.003 | 0.921 | Anticonvulsant | 0.897 0.004 DBMET03216 0.732 0.005 DBMET01170 | ||
| 0.634 | 0.009 | 0.634 | Immunomodulator | 0.554 0.016 DBMET03216 | ||
| 0.55 | 0.023 | 0.55 | Immunostimulant | 0.314 0.075 DBMET03216 0.31 0.076 DBMET01170 | ||
| 0.524 | 0.006 | 0.534 | Anesthetic general | 0.283 0.038 DBMET03216 0.534 0.006 DBMET01170 | DBMET01170 | |
| 0.497 | 0.004 | 0.497 | DNA directed RNA polymerase inhibitor | 0.269 0.008 DBMET03216 0.147 0.025 DBMET01170 | ||
| 0.501 | 0.011 | 0.501 | RNA-directed DNA polymerase inhibitor | 0.303 0.031 DBMET03216 0.347 0.024 DBMET01170 | ||
| 0.534 | 0.049 | 0.534 | Caspase 9 stimulant | 0.4 0.111 DBMET03216 0.486 0.066 DBMET01170 | ||
| 0.473 | 0.018 | 0.473 | Cardiotonic | 0.241 0.088 DBMET03216 0.311 0.052 DBMET01170 | ||
| 0.428 | 0.018 | 0.428 | Angiogenesis stimulant | |||
| 0.382 | 0.03 | 0.382 | Tumour necrosis factor alpha release inhibitor | |||
| 0.369 | 0.026 | 0.369 | DNA synthesis inhibitor | 0.237 0.076 DBMET03216 0.277 0.052 DBMET01170 | ||
| 0.344 | 0.004 | 0.344 | Nav1.8 sodium channel blocker | |||
| 0.344 | 0.008 | 0.344 | UDP-glucose 4-epimerase inhibitor | 0.147 0.03 DBMET03216 0.268 0.012 DBMET01170 | ||
| 0.32 | 0.01 | 0.32 | DNA polymerase I inhibitor | |||
| 0.29 | 0.009 | 0.759 | Nav1.1 sodium channel blocker | 0.47 0.004 DBMET03216 0.759 0.002 DBMET01170 | DBMET01170 | |
| 0.287 | 0.013 | 0.287 | Aldehyde dehydrogenase inhibitor | |||
| 0.264 | 0.006 | 0.264 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.265 | 0.008 | 0.265 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.108 0.047 DBMET03216 0.212 0.014 DBMET01170 | ||
| 0.257 | 0.005 | 0.598 | Aldose reductase inhibitor | 0.542 0.003 DBMET03216 0.598 0.003 DBMET01170 | DBMET01170 | |
| 0.254 | 0.005 | 0.254 | Potassium channel large-conductance Ca-activated activator | |||
| 0.267 | 0.022 | 0.267 | Bone formation stimulant | |||
| 0.229 | 0.004 | 0.229 | Viral attachment inhibitor | |||
| 0.227 | 0.008 | 0.231 | HIV-1 reverse transcriptase inhibitor | 0.231 0.008 DBMET03216 0.068 0.051 DBMET01170 | DBMET03216 | |
| 0.219 | 0.006 | 0.219 | Sphingosine 1-phosphate receptor 5 antagonist | 0.135 0.089 DBMET03216 0.128 0.106 DBMET01170 | ||
| 0.261 | 0.066 | 0.261 | Antiamyloidogenic | |||
| 0.196 | 0.006 | 0.196 | Biliverdin reductase inhibitor | 0.085 0.024 DBMET03216 0.15 0.009 DBMET01170 | ||
| 0.194 | 0.011 | 0.194 | NADH dehydrogenase inhibitor | 0.105 0.039 DBMET03216 0.153 0.017 DBMET01170 | ||
| 0.189 | 0.011 | 0.189 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.188 | 0.012 | 0.188 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.186 | 0.017 | 0.186 | Adenylate kinase inhibitor | 0.098 0.071 DBMET03216 0.119 0.045 DBMET01170 | ||
| 0.197 | 0.032 | 0.197 | Mannose-6-phosphate isomerase inhibitor | 0.161 0.055 DBMET01170 | ||
| 0.315 | 0.154 | 0.368 | DNA directed DNA polymerase inhibitor | 0.221 0.212 DBMET03216 0.368 0.13 DBMET01170 | DBMET01170 | |
| 0.227 | 0.067 | 0.227 | Psychostimulant | |||
| 0.162 | 0.01 | 0.162 | Carbamoyl phosphate synthetase inhibitor | 0.081 0.028 DBMET03216 0.1 0.021 DBMET01170 | ||
| 0.168 | 0.016 | 0.168 | Triose-phosphate isomerase inhibitor | 0.083 0.07 DBMET03216 0.108 0.041 DBMET01170 | ||
| 0.154 | 0.003 | 0.154 | Purinergic P2Y2 antagonist | 0.054 0.009 DBMET03216 0.037 0.019 DBMET01170 | ||
| 0.151 | 0.004 | 0.151 | Sphingosine 1-phosphate receptor 3 agonist | |||
| 0.158 | 0.019 | 0.158 | Porphobilinogen synthase inhibitor | 0.083 0.045 DBMET01170 | ||
| 0.144 | 0.005 | 0.187 | Cathepsin E inhibitor | 0.15 0.005 DBMET03216 0.187 0.004 DBMET01170 | DBMET01170 | |
| 0.149 | 0.012 | 0.149 | Purinergic P2X2 antagonist | |||
| 0.269 | 0.135 | 0.269 | Immunosuppressant | |||
| 0.17 | 0.037 | 0.17 | Alkylator | 0.105 0.083 DBMET01170 | ||
| 0.141 | 0.009 | 0.141 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.065 0.029 DBMET03216 0.104 0.013 DBMET01170 | ||
| 0.197 | 0.074 | 0.197 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.169 0.11 DBMET01170 | ||
| 0.141 | 0.02 | 0.141 | Phosphofructokinase-1 inhibitor | 0.104 0.03 DBMET01170 | ||
| 0.149 | 0.028 | 0.149 | Potassium channel (Ca-activated) activator | |||
| 0.127 | 0.014 | 0.127 | Argininosuccinate synthase inhibitor | 0.093 0.021 DBMET01170 | ||
| 0.122 | 0.022 | 0.122 | Glutamate dehydrogenase inhibitor | 0.078 0.047 DBMET01170 | ||
| 0.113 | 0.014 | 0.113 | Antimetabolite | 0.05 0.031 DBMET03216 0.042 0.038 DBMET01170 | ||
| 0.097 | 0.003 | 0.097 | Uridine phosphorylase inhibitor | 0.078 0.004 DBMET03216 0.069 0.004 DBMET01170 | ||
| 0.099 | 0.01 | 0.099 | Elastase inhibitor | |||
| 0.165 | 0.079 | 0.165 | Phospholipase C inhibitor | |||
| 0.09 | 0.007 | 0.09 | Thymidine kinase inhibitor | 0.058 0.014 DBMET03216 0.063 0.013 DBMET01170 | ||
| 0.092 | 0.01 | 0.092 | Sphingosine 1-phosphate receptor 5 agonist | |||
| 0.093 | 0.014 | 0.093 | Glutamate (mGluR6) antagonist | 0.063 0.056 DBMET03216 0.078 0.027 DBMET01170 | ||
| 0.157 | 0.079 | 0.157 | Interleukin 6 antagonist | |||
| 0.14 | 0.063 | 0.14 | Toll-Like receptor antagonist | |||
| 0.253 | 0.18 | 0.323 | Analgesic | 0.323 0.125 DBMET01170 | DBMET01170 | |
| 0.077 | 0.005 | 0.077 | Purinergic P2X agonist | |||
| 0.087 | 0.016 | 0.087 | Autotaxin inhibitor | |||
| 0.079 | 0.008 | 0.079 | Thymidylate synthase inhibitor | 0.051 0.026 DBMET01170 | ||
| 0.097 | 0.028 | 0.097 | Carbonic anhydrase V inhibitor | 0.072 0.041 DBMET01170 | ||
| 0.233 | 0.167 | 0.252 | Calcium channel activator | 0.252 0.145 DBMET01170 | DBMET01170 | |
| 0.116 | 0.05 | 0.116 | DOPA decarboxylase inhibitor | 0.107 0.063 DBMET01170 | ||
| 0.11 | 0.049 | 0.11 | Folate antagonist | |||
| 0.084 | 0.023 | 0.084 | TRPA1 antagonist | 0.054 0.053 DBMET01170 | ||
| 0.095 | 0.035 | 0.095 | D-Ala-D-Ala ligase inhibitor | 0.083 0.059 DBMET01170 | ||
| 0.064 | 0.006 | 0.064 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.027 0.02 DBMET03216 0.04 0.012 DBMET01170 | ||
| 0.079 | 0.022 | 0.079 | Ornithine carbamoyltransferase inhibitor | 0.06 0.031 DBMET01170 | ||
| 0.07 | 0.017 | 0.07 | Ryanodine receptor antagonist | 0.062 0.032 DBMET03216 0.063 0.03 DBMET01170 | ||
| 0.137 | 0.086 | 0.137 | Heat shock protein 70 antagonist | 0.129 0.128 DBMET01170 | ||
| 0.103 | 0.054 | 0.103 | Glutamate (mGluR7) agonist | |||
| 0.086 | 0.039 | 0.086 | Histidine decarboxylase inhibitor | 0.071 0.05 DBMET01170 | ||
| 0.075 | 0.028 | 0.075 | Purinergic P2X1 antagonist | |||
| 0.092 | 0.046 | 0.124 | Hematopoietic | 0.124 0.021 DBMET03216 | DBMET03216 | |
| 0.054 | 0.012 | 0.054 | Fumarate hydratase inhibitor | 0.041 0.018 DBMET01170 | ||
| 0.048 | 0.005 | 0.048 | Growth factor receptor-bound protein 2 antagonist | 0.032 0.031 DBMET01170 | ||
| 0.051 | 0.01 | 0.137 | Calcitonin gene-related peptide antagonist | 0.058 0.007 DBMET03216 0.137 0.003 DBMET01170 | DBMET01170 | |
| 0.096 | 0.056 | 0.257 | Alcohol dehydrogenase inhibitor | 0.257 0.007 DBMET01170 | DBMET01170 | |
| 0.207 | 0.168 | 0.268 | Vasodilator, peripheral | 0.268 0.115 DBMET03216 | DBMET03216 | |
| 0.042 | 0.004 | 0.042 | Purinergic P2 agonist | |||
| 0.042 | 0.004 | 0.042 | Purinergic receptor agonist | |||
| 0.043 | 0.004 | 0.043 | Toll-Like receptor 4 agonist | |||
| 0.058 | 0.021 | 0.058 | Glucose-6-phosphate isomerase inhibitor | 0.044 0.04 DBMET01170 | ||
| 0.066 | 0.032 | 0.066 | Potassium channel (Ca-activated) blocker | |||
| 0.096 | 0.064 | 0.096 | Sphingomyelinase inhibitor | |||
| 0.036 | 0.004 | 0.036 | Purinergic P2Y agonist | |||
| 0.075 | 0.043 | 0.075 | Toll-Like receptor 7 antagonist | |||
| 0.09 | 0.058 | 0.09 | Aminoacyl-tRNA synthetase inhibitor | |||
| 0.063 | 0.031 | 0.063 | Acyl-CoA dehydrogenase inhibitor | 0.047 0.046 DBMET01170 | ||
| 0.036 | 0.004 | 0.036 | Purinergic P2Y1 antagonist | |||
| 0.099 | 0.071 | 0.099 | Toll-Like receptor 4 antagonist | |||
| 0.027 | 0.002 | 0.027 | Mannitol 2-dehydrogenase inhibitor | |||
| 0.031 | 0.01 | 0.033 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.033 0.009 DBMET03216 0.033 0.008 DBMET01170 | DBMET01170 | |
| 0.146 | 0.125 | 0.146 | Antimitotic | |||
| 0.047 | 0.025 | 0.047 | Glutamate (mGluR group III) antagonist | 0.043 0.032 DBMET01170 | ||
| 0.049 | 0.027 | 0.049 | Purinergic P2X4 antagonist | |||
| 0.071 | 0.05 | 0.132 | Phospholipase D inhibitor | 0.081 0.033 DBMET03216 0.132 0.004 DBMET01170 | DBMET01170 | |
| 0.045 | 0.025 | 0.045 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.028 | 0.009 | 0.028 | Inosine monophosphate dehydrogenase 1 inhibitor | |||
| 0.075 | 0.057 | 0.075 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.054 | 0.038 | 0.097 | Cathepsin D inhibitor | 0.097 0.02 DBMET03216 0.053 0.039 DBMET01170 | DBMET03216 | |
| 0.029 | 0.013 | 0.043 | Thymidine phosphorylase inhibitor | 0.025 0.022 DBMET03216 0.043 0.006 DBMET01170 | DBMET01170 | |
| 0.038 | 0.026 | 0.038 | Glutamate (mGluR8) agonist | |||
| 0.157 | 0.146 | 0.239 | Vasodilator | 0.239 0.075 DBMET01170 | DBMET01170 | |
| 0.125 | 0.114 | 0.139 | Adenylate cyclase stimulant | 0.139 0.083 DBMET01170 | DBMET01170 | |
| 0.097 | 0.087 | 0.099 | Adenylate cyclase inhibitor | 0.099 0.085 DBMET01170 | DBMET01170 | |
| 0.048 | 0.04 | 0.048 | Antiviral (Hepatitis D) | |||
| 0.013 | 0.006 | 0.013 | Purine nucleoside phosphorylase inhibitor | |||
| 0.089 | 0.083 | 0.089 | Expectorant | |||
| 0.041 | 0.036 | 0.043 | Phosphorylase inhibitor | 0.043 0.035 DBMET01170 | DBMET01170 | |
| 0.011 | 0.006 | 0.011 | Purinergic P2Y2 agonist | |||
| 0.059 | 0.056 | 0.059 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.04 | 0.037 | 0.04 | Sphingosine 1-phosphate receptor agonist | |||
| 0.139 | 0.136 | 0.139 | Catenin beta inhibitor | |||
| 0.004 | 0.003 | 0.004 | Purinergic P2Y4 agonist | |||
| 0.023 | 0.022 | 0.023 | Lysophosphatidic acid receptor 1 agonist | |||
| 0.045 | 0.044 | 0.045 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.07 | 0.075 | 0.099 | Glycine receptor antagonist | 0.099 0.033 DBMET01170 | DBMET01170 | |
| 0.025 | 0.031 | 0.033 | DNA polymerase III inhibitor | 0.03 0.014 DBMET03216 0.033 0.01 DBMET01170 | DBMET01170 | |
| 0.044 | 0.051 | 0.077 | Carbonic anhydrase VB inhibitor | 0.077 0.024 DBMET01170 | DBMET01170 | |
| 0.18 | 0.188 | 0.279 | Nootropic | 0.279 0.085 DBMET01170 | DBMET01170 | |
| 0.056 | 0.067 | 0.079 | Carbonic anhydrase VA inhibitor | 0.079 0.037 DBMET01170 | DBMET01170 | |
| 0.081 | 0.095 | 0.107 | Anabolic | 0.107 0.054 DBMET01170 | DBMET01170 | |
| 0.064 | 0.08 | 0.102 | Keratolytic | 0.102 0.029 DBMET01170 | DBMET01170 | |
| 0.225 | 0.241 | 0.431 | Cyclophilin D inhibitor | 0.431 0.075 DBMET03216 0.366 0.111 DBMET01170 | DBMET03216 | |
| 0.072 | 0.096 | 0.119 | Phosphodiesterase I inhibitor | 0.119 0.028 DBMET01170 | DBMET01170 | |
| 0.096 | 0.144 | 0.158 | DNA repair enzyme inhibitor | 0.158 0.025 DBMET01170 | DBMET01170 | |
| 0.009 | 0.066 | 0.014 | DNA polymerase III polC-type inhibitor | 0.013 0.011 DBMET03216 0.014 0.007 DBMET01170 | DBMET01170 | |
| 0.033 | 0.089 | 0.062 | HIV-1 integrase (Strand Transfer) inhibitor | 0.062 0.04 DBMET03216 | DBMET03216 | |
| 0.039 | 0.096 | 0.061 | HIV-1 integrase (3'-Processing) inhibitor | 0.061 0.046 DBMET03216 | DBMET03216 | |
| 0.008 | 0.068 | 0.131 | Calcitonin gene-related peptide 1 receptor antagonist | 0.015 0.014 DBMET03216 0.131 0.003 DBMET01170 | DBMET01170 | |
| 0.098 | 0.162 | 0.125 | Arachidonic acid antagonist | 0.125 0.119 DBMET01170 | DBMET01170 | |
| 0.065 | 0.13 | 0.299 | Phosphodiesterase 7B inhibitor | 0.141 0.025 DBMET03216 0.299 0.004 DBMET01170 | DBMET01170 | |
| 0.033 | 0.107 | 0.178 | Phosphodiesterase 7A inhibitor | 0.069 0.012 DBMET03216 0.178 0.003 DBMET01170 | DBMET01170 | |
| 0.069 | 0.146 | 0.126 | GABA C receptor antagonist | 0.126 0.047 DBMET01170 | DBMET01170 | |
| 0.04 | 0.125 | 0.059 | Corticotropin releasing factor 2 receptor antagonist | 0.059 0.049 DBMET01170 | DBMET01170 | |
| 0.002 | 0.088 | 0.017 | DNA topoisomerase III inhibitor | 0.017 0.002 DBMET01170 | DBMET01170 | |
| 0.005 | 0.092 | 0.049 | Nociceptin (N/OFQ) receptor agonist | 0.049 0.005 DBMET01170 | DBMET01170 | |
| 0.116 | 0.206 | 0.346 | Spasmolytic | 0.313 0.065 DBMET03216 0.346 0.054 DBMET01170 | DBMET01170 | |
| 0.06 | 0.164 | 0.128 | GABA C receptor rho-1 antagonist | 0.128 0.034 DBMET01170 | DBMET01170 | |
| 0.048 | 0.177 | 0.122 | Creatine kinase inhibitor | 0.088 0.075 DBMET03216 0.122 0.039 DBMET01170 | DBMET01170 | |
| 0.031 | 0.163 | 0.081 | Glutamate decarboxylase inhibitor | 0.081 0.044 DBMET01170 | DBMET01170 | |
| 0.02 | 0.167 | 0.108 | NMDA receptor glycine site agonist | 0.108 0.013 DBMET01170 | DBMET01170 | |
| 0.086 | 0.236 | 0.178 | Interleukin agonist | 0.178 0.141 DBMET01170 | DBMET01170 | |
| 0.022 | 0.172 | 0.056 | Kainate receptor agonist | 0.046 0.019 DBMET03216 0.056 0.009 DBMET01170 | DBMET01170 | |
| 0.087 | 0.24 | 0.433 | Tumour necrosis factor antagonist | 0.19 0.06 DBMET03216 0.433 0.005 DBMET01170 | DBMET01170 | |
| 0.019 | 0.182 | 0.275 | Phosphodiesterase VII inhibitor | 0.091 0.017 DBMET03216 0.275 0.003 DBMET01170 | DBMET01170 | |
| 0.023 | 0.186 | 0.049 | Glutamate (mGluR4) antagonist | 0.049 0.022 DBMET01170 | DBMET01170 | |
| 0.104 | 0.268 | 0.186 | DNA damaging | 0.186 0.128 DBMET01170 | DBMET01170 | |
| 0.037 | 0.203 | 0.093 | Aminopeptidase B inhibitor | 0.093 0.07 DBMET01170 | DBMET01170 | |
| 0.012 | 0.179 | 0.053 | NMDA 2A receptor antagonist | 0.053 0.035 DBMET01170 | DBMET01170 | |
| 0.051 | 0.229 | 0.156 | Sodium channel (voltage-gated) blocker | 0.156 0.05 DBMET01170 | DBMET01170 | |
| 0.033 | 0.219 | 0.073 | HIV-1 integrase inhibitor | 0.073 0.045 DBMET03216 | DBMET03216 | |
| 0.012 | 0.2 | 0.076 | NMDA 2C receptor antagonist | 0.076 0.028 DBMET01170 | DBMET01170 | |
| 0.011 | 0.205 | 0.055 | Angiotensin AT1 receptor antagonist | 0.055 0.012 DBMET03216 0.039 0.035 DBMET01170 | DBMET03216 | |
| 0.009 | 0.204 | 0.05 | Nicotinic acid receptor agonist | 0.05 0.014 DBMET01170 | DBMET01170 | |
| 0.05 | 0.245 | 0.22 | Alpha-N-acetylglucosaminidase inhibitor | 0.169 0.045 DBMET03216 0.22 0.029 DBMET01170 | DBMET01170 | |
| 0.039 | 0.241 | 0.193 | GABA C receptor agonist | 0.135 0.041 DBMET03216 0.193 0.022 DBMET01170 | DBMET01170 | |
| 0.017 | 0.223 | 0.06 | Matrix metalloproteinase (membrane-type) inhibitor | 0.06 0.033 DBMET01170 | DBMET01170 | |
| 0.025 | 0.232 | 0.095 | NMDA receptor agonist | 0.095 0.021 DBMET01170 | DBMET01170 | |
| 0.038 | 0.247 | 0.234 | Ferrochelatase inhibitor | 0.156 0.035 DBMET03216 0.234 0.016 DBMET01170 | DBMET01170 | |
| 0.002 | 0.213 | 0.018 | Angiotensin AT1B receptor antagonist | 0.018 0.007 DBMET03216 | DBMET03216 | |
| 0.048 | 0.258 | 0.132 | Sodium channel blocker | 0.132 0.072 DBMET01170 | DBMET01170 | |
| 0.027 | 0.239 | 0.122 | Metalloproteinase-9 inhibitor | 0.122 0.024 DBMET01170 | DBMET01170 | |
| 0.018 | 0.238 | 0.091 | Matrix metalloproteinase inhibitor | 0.091 0.031 DBMET01170 | DBMET01170 | |
| 0.011 | 0.233 | 0.04 | Angiotensin II receptor antagonist | 0.04 0.015 DBMET03216 | DBMET03216 | |
| 0.084 | 0.324 | 0.267 | Cyclic AMP phosphodiesterase inhibitor | 0.267 0.056 DBMET01170 | DBMET01170 | |
| 0.018 | 0.259 | 0.058 | Androgen agonist | 0.058 0.043 DBMET01170 | DBMET01170 | |
| 0.052 | 0.296 | 0.127 | Acetylcholine M1 receptor antagonist | 0.127 0.099 DBMET01170 | DBMET01170 | |
| 0.017 | 0.267 | 0.058 | Aconitate hydratase inhibitor | 0.058 0.028 DBMET01170 | DBMET01170 | |
| 0.002 | 0.252 | 0.012 | Egl nine homolog 3 inhibitor | 0.012 0.009 DBMET01170 | DBMET01170 | |
| 0.022 | 0.279 | 0.126 | Metalloproteinase-2 inhibitor | 0.126 0.027 DBMET01170 | DBMET01170 | |
| 0.009 | 0.266 | 0.039 | Dopamine D5 agonist | 0.039 0.029 DBMET01170 | DBMET01170 | |
| 0.012 | 0.274 | 0.079 | Alcohol oxidase inhibitor | 0.049 0.047 DBMET03216 0.079 0.025 DBMET01170 | DBMET01170 | |
| 0.116 | 0.379 | 0.287 | Tyrosine 3 hydroxylase inhibitor | 0.232 0.087 DBMET03216 0.287 0.04 DBMET01170 | DBMET01170 | |
| 0.113 | 0.378 | 0.483 | GABA C receptor rho-3 antagonist | 0.282 0.128 DBMET03216 0.483 0.031 DBMET01170 | DBMET01170 | |
| 0.099 | 0.368 | 0.148 | Ca2+-transporting ATPase inhibitor | 0.134 0.098 DBMET03216 0.148 0.047 DBMET01170 | DBMET01170 | |
| 0.007 | 0.286 | 0.031 | Acid ceramidase inhibitor | 0.031 0.008 DBMET01170 | DBMET01170 | |
| 0.006 | 0.291 | 0.028 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.028 0.005 DBMET01170 | DBMET01170 | |
| 0.006 | 0.291 | 0.048 | Nicotinic acid receptor 2 antagonist | 0.048 0.004 DBMET01170 | DBMET01170 | |
| 0.022 | 0.324 | 0.089 | Glutamate (mGluR7) antagonist | 0.062 0.06 DBMET03216 0.089 0.018 DBMET01170 | DBMET01170 | |
| 0.085 | 0.392 | 0.251 | Neuropeptide Y2 antagonist | 0.235 0.071 DBMET03216 0.251 0.055 DBMET01170 | DBMET01170 | |
| 0.012 | 0.322 | 0.038 | Plasmepsin II inhibitor | 0.038 0.035 DBMET01170 | DBMET01170 | |
| 0.009 | 0.322 | 0.091 | Neutrophil collagenase inhibitor | 0.091 0.026 DBMET01170 | DBMET01170 | |
| 0.027 | 0.342 | 0.14 | Cystathionine beta-synthase inhibitor | 0.097 0.08 DBMET03216 0.14 0.045 DBMET01170 | DBMET01170 | |
| 0.021 | 0.338 | 0.09 | Dihydroorotate oxidase inhibitor | 0.09 0.007 DBMET01170 | DBMET01170 | |
| 0.159 | 0.477 | 0.467 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.342 0.16 DBMET03216 0.467 0.051 DBMET01170 | DBMET01170 | |
| 0.014 | 0.334 | 0.084 | Phenylalanine 4-hydroxylase inhibitor | 0.084 0.035 DBMET01170 | DBMET01170 | |
| 0.019 | 0.359 | 0.059 | Pregnane X receptor antagonist | 0.059 0.034 DBMET01170 | DBMET01170 | |
| 0.072 | 0.413 | 0.152 | Histone acetyltransferase inhibitor | 0.152 0.136 DBMET01170 | DBMET01170 | |
| 0.004 | 0.35 | 0.025 | Glutamate (mGluR1a) agonist | 0.025 0.012 DBMET01170 | DBMET01170 | |
| 0.051 | 0.4 | 0.198 | GABA C receptor rho-2 antagonist | 0.128 0.11 DBMET03216 0.198 0.03 DBMET01170 | DBMET01170 | |
| 0.041 | 0.392 | 0.258 | Peroxidase inhibitor | 0.129 0.092 DBMET03216 0.258 0.046 DBMET01170 | DBMET01170 | |
| 0.038 | 0.396 | 0.088 | Phosphodiesterase 6D inhibitor | 0.088 0.08 DBMET01170 | DBMET01170 | |
| 0.02 | 0.383 | 0.059 | Bombesin 2 receptor antagonist | 0.059 0.025 DBMET01170 | DBMET01170 | |
| 0.081 | 0.45 | 0.268 | Histamine release inhibitor | 0.205 0.197 DBMET03216 0.268 0.143 DBMET01170 | DBMET01170 | |
| 0.009 | 0.386 | 0.044 | Dihydroorotase inhibitor | 0.044 0.032 DBMET01170 | DBMET01170 | |
| 0.019 | 0.4 | 0.095 | Phosphodiesterase 1A inhibitor | 0.095 0.011 DBMET01170 | DBMET01170 | |
| 0.024 | 0.408 | 0.075 | Glycine receptor agonist | 0.075 0.046 DBMET01170 | DBMET01170 | |
| 0.042 | 0.428 | 0.536 | Aldehyde oxidase inhibitor | 0.237 0.087 DBMET03216 0.536 0.028 DBMET01170 | DBMET01170 | |
| 0.008 | 0.395 | 0.027 | Glutamate (mGluR1) agonist | 0.027 0.013 DBMET01170 | DBMET01170 | |
| 0.046 | 0.436 | 0.174 | Succinate dehydrogenase inhibitor | 0.147 0.119 DBMET03216 0.174 0.075 DBMET01170 | DBMET01170 | |
| 0.029 | 0.422 | 0.116 | Electrolyte absorption antagonist | 0.091 0.072 DBMET03216 0.116 0.04 DBMET01170 | DBMET01170 | |
| 0.01 | 0.41 | 0.104 | Collagenase 3 inhibitor | 0.104 0.015 DBMET01170 | DBMET01170 | |
| 0.031 | 0.436 | 0.089 | Granulocyte macrophage colony stimulating factor agonist | 0.089 0.054 DBMET01170 | DBMET01170 | |
| 0.011 | 0.421 | 0.081 | Cannabinoid CB1 receptor antagonist | 0.081 0.026 DBMET01170 | DBMET01170 | |
| 0.022 | 0.436 | 0.157 | 5 Hydroxytryptamine 3A agonist | 0.157 0.032 DBMET01170 | DBMET01170 | |
| 0.009 | 0.427 | 0.057 | Protein kinase (CK2) beta inhibitor | 0.057 0.005 DBMET01170 | DBMET01170 | |
| 0.022 | 0.441 | 0.163 | Diuretic | 0.163 0.066 DBMET03216 | DBMET03216 | |
| 0.007 | 0.446 | 0.086 | Acetylcholine M5 receptor agonist | 0.086 0.029 DBMET01170 | DBMET01170 | |
| 0.054 | 0.493 | 0.281 | Superoxide dismutase inhibitor | 0.192 0.126 DBMET03216 0.281 0.058 DBMET01170 | DBMET01170 | |
| 0.006 | 0.452 | 0.024 | Integrin alpha2beta1 antagonist | 0.024 0.023 DBMET01170 | DBMET01170 | |
| 0.019 | 0.483 | 0.087 | Prolactin inhibitor | 0.087 0.07 DBMET01170 | DBMET01170 | |
| 0.083 | 0.55 | 0.223 | Nitric-oxide synthase stimulant | 0.223 0.056 DBMET01170 | DBMET01170 | |
| 0.018 | 0.487 | 0.083 | Phosphodiesterase 1B inhibitor | 0.083 0.021 DBMET01170 | DBMET01170 | |
| 0.004 | 0.478 | 0.037 | Nociceptin (N/OFQ) receptor antagonist | 0.037 0.023 DBMET01170 | DBMET01170 | |
| 0.097 | 0.574 | 0.194 | 5 Hydroxytryptamine 3E antagonist | 0.194 0.072 DBMET01170 | DBMET01170 | |
| 0.011 | 0.494 | 0.112 | Secretase beta inhibitor | 0.07 0.049 DBMET03216 0.112 0.013 DBMET01170 | DBMET01170 | |
| 0.004 | 0.507 | 0.096 | Alpha 1a adrenoreceptor antagonist | 0.096 0.038 DBMET01170 | DBMET01170 | |
| 0.025 | 0.532 | 0.082 | MDM2 inhibitor | 0.082 0.017 DBMET01170 | DBMET01170 | |
| 0.09 | 0.598 | 0.248 | 5 Hydroxytryptamine uptake stimulant | 0.248 0.083 DBMET01170 | DBMET01170 | |
| 0.006 | 0.527 | 0.078 | Cannabinoid receptor antagonist | 0.078 0.041 DBMET01170 | DBMET01170 | |
| 0.01 | 0.532 | 0.069 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.069 0.063 DBMET01170 | DBMET01170 | |
| 0.046 | 0.57 | 0.279 | Growth hormone agonist | 0.279 0.037 DBMET01170 | DBMET01170 | |
| 0.021 | 0.545 | 0.14 | HIV-1 integrase (Overall Integration) inhibitor | 0.14 0.029 DBMET01170 | DBMET01170 | |
| 0.028 | 0.555 | 0.319 | DNA polymerase beta inhibitor | 0.319 0.155 DBMET01170 | DBMET01170 | |
| 0.059 | 0.596 | 0.25 | 5 Hydroxytryptamine release stimulant | 0.25 0.089 DBMET01170 | DBMET01170 | |
| 0.003 | 0.547 | 0.022 | Thyroid hormone alpha agonist | 0.022 0.006 DBMET01170 | DBMET01170 | |
| 0.077 | 0.631 | 0.268 | Peptidyltransferase inhibitor | 0.268 0.039 DBMET01170 | DBMET01170 | |
| 0.005 | 0.572 | 0.083 | Alpha 1 adrenoreceptor antagonist | 0.083 0.051 DBMET01170 | DBMET01170 | |
| 0.015 | 0.597 | 0.086 | Phosphodiesterase 1C inhibitor | 0.086 0.015 DBMET01170 | DBMET01170 | |
| 0.035 | 0.619 | 0.088 | CC chemokine 5 receptor agonist | 0.088 0.042 DBMET01170 | DBMET01170 | |
| 0.019 | 0.604 | 0.107 | Acetylcholine release stimulant | 0.107 0.072 DBMET01170 | DBMET01170 | |
| 0.008 | 0.594 | 0.08 | Alpha adrenoreceptor antagonist | 0.08 0.072 DBMET01170 | DBMET01170 | |
| 0.01 | 0.601 | 0.122 | Topoisomerase I inhibitor | 0.122 0.054 DBMET03216 | DBMET03216 | |
| 0.008 | 0.6 | 0.077 | Protein kinase C beta inhibitor | 0.077 0.034 DBMET03216 | DBMET03216 | |
| 0.032 | 0.645 | 0.137 | CF transmembrane conductance regulator agonist | 0.137 0.101 DBMET01170 | DBMET01170 | |
| 0.003 | 0.616 | 0.051 | Alpha 1d adrenoreceptor antagonist | 0.051 0.048 DBMET01170 | DBMET01170 | |
| 0.003 | 0.619 | 0.065 | Alpha 1b adrenoreceptor antagonist | 0.065 0.057 DBMET01170 | DBMET01170 | |
| 0.017 | 0.642 | 0.127 | Bromodomain-containing protein 2 inhibitor | 0.127 0.019 DBMET01170 | DBMET01170 | |
| 0.004 | 0.669 | 0.045 | Macrophage elastase inhibitor | 0.045 0.028 DBMET01170 | DBMET01170 | |
| 0.014 | 0.686 | 0.219 | Nav1.2 sodium channel blocker | 0.219 0.028 DBMET01170 | DBMET01170 | |
| 0.042 | 0.719 | 0.314 | 5 Hydroxytryptamine release inhibitor | 0.314 0.15 DBMET01170 | DBMET01170 | |
| 0.027 | 0.711 | 0.251 | Gastrin inhibitor | 0.251 0.078 DBMET01170 | DBMET01170 | |
| 0.009 | 0.705 | 0.197 | Beta lactamase inhibitor | 0.197 0.187 DBMET01170 | DBMET01170 | |
| 0.008 | 0.709 | 0.051 | Nicotinic acid receptor 1 agonist | 0.051 0.02 DBMET01170 | DBMET01170 | |
| 0.028 | 0.735 | 0.229 | Insulysin inhibitor | 0.229 0.118 DBMET01170 | DBMET01170 | |
| 0.005 | 0.728 | 0.093 | Protein kinase C gamma inhibitor | 0.093 0.09 DBMET03216 | DBMET03216 | |
| 0.072 | 0.797 | 0.235 | Calcium channel L-type activator | 0.235 0.222 DBMET01170 | DBMET01170 | |
| 0.018 | 0.746 | 0.171 | Neurotensin receptor agonist | 0.171 0.06 DBMET01170 | DBMET01170 | |
| 0.007 | 0.742 | 0.15 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.15 0.142 DBMET01170 | DBMET01170 | |
| 0.009 | 0.746 | 0.231 | Nav1.6 sodium channel blocker | 0.231 0.012 DBMET01170 | DBMET01170 | |
| 0.019 | 0.762 | 0.153 | 3C-like protease (Human coronavirus) inhibitor | 0.153 0.097 DBMET01170 | DBMET01170 | |
| 0.009 | 0.753 | 0.171 | Cyclin-dependent kinase 8 inhibitor | 0.171 0.06 DBMET01170 | DBMET01170 | |
| 0.005 | 0.762 | 0.038 | Protein kinase C beta I inhibitor | 0.038 0.011 DBMET03216 | DBMET03216 | |
| 0.004 | 0.766 | 0.034 | Protein kinase C beta II inhibitor | 0.034 0.019 DBMET03216 | DBMET03216 | |
| 0.005 | 0.778 | 0.158 | Phosphodiesterase III inhibitor | 0.158 0.009 DBMET01170 | DBMET01170 | |
| 0.015 | 0.792 | 0.148 | ATPase inhibitor | 0.148 0.104 DBMET01170 | DBMET01170 | |
| 0.013 | 0.797 | 0.194 | Nav1.3 sodium channel blocker | 0.194 0.027 DBMET01170 | DBMET01170 | |
| 0.005 | 0.84 | 0.226 | Thioredoxin glutathione reductase inhibitor | 0.226 0.151 DBMET03216 0.196 0.176 DBMET01170 | DBMET03216 | |
| 0.013 | 0.884 | 0.106 | Interleukin 5 antagonist | 0.106 0.035 DBMET01170 | DBMET01170 | |
| 0.004 | 0.916 | 0.066 | Protein kinase C eta inhibitor | 0.066 0.03 DBMET03216 | DBMET03216 | |
| 0.003 | 0.935 | 0.041 | Nicotinic acid receptor 2 agonist | 0.041 0.02 DBMET01170 | DBMET01170 | |
| 0.005 | 0.959 | 0.036 | Aggrecanase 1 inhibitor | 0.036 0.035 DBMET01170 | DBMET01170 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |